.
MergerLinks Header Logo

Announced

Germany to invest $337m in CureVac.

Financials

Edit Data
Transaction Value£266m
Consideration TypeCash
Capital Owned-
Capital Bid For23%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

biopharmaceuticals

Single Bidder

Pharmaceuticals

Germany

Acquisition

Private

Pending

Friendly

Minority

Synopsis

Edit

The Federal Republic of Germany agreed to invest $337m in CureVac, a biopharmaceutical company headquartered in Tübingen, that develops therapies based on messenger RNA. Under the agreement, the state will hold a stake of around 23% in CureVac. "We are very excited that, with the Federal Republic of Germany and dievini, we have such strong and reliable partners at our side. This strong financial commitment provides us further cash reach and stability for the accelerated development of our mRNA platform, the development and production of our current and additional mRNA vaccine and drug candidates, as well as the strategic expansion of our organization. At the same time we will retain full operational and strategic independence," Franz-Werner Haas, CureVac Acting CEO and COO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US